Opinion|Videos|February 9, 2026
The Role of Tumor Burden on Treatment Selection in EGFR-Mutated NSCLC
Author(s)Narjust Florez, MD
High tumor burden lung cancer demands fast action: start chemo while awaiting biomarkers, then add osimertinib for rapid symptom relief.
Advertisement
Episodes in this series
Narjust Florez, MD, explores how baseline tumor burden may influence therapeutic decision-making in EGFR-mutated non–small cell lung cancer (NSCLC). Florez discusses associations between disease volume, symptom burden, and urgency of response when considering systemic therapy options. She highlights how tumor burden can help frame risk–benefit discussions, particularly when balancing rapid disease control against potential toxicity.
Advertisement
Related to this article
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Advertisement
Advertisement
Trending on OncLive
1
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
2
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
3
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5